Richard Furie, MD

Richard Furie, MD, discusses phase 2 JASMINE data showing sustained SRI-4 and LLDAS responses through 52 weeks.

Richard Furie, MD, discusses a post hoc analysis of BLISS-LN showing a markedly slower rate of kidney function loss with belimumab versus PBO.

Furie discussed topline data from the REGENCY trial and key secondary endpoints.

Furie discussed his experiences in evaluating therapies such as rituximab and now obinutuzumab for lupus nephritis.